雷莫芦单抗 ramucirumab

Drug Class

VEGFR-2 antagonist monoclonal antibody

Mechanism

Binds specifically to VEGFR-2, blocking the binding of VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting ligand-induced activation of VEGFR-2 and downstream angiogenesis.

Approved Indication

Treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, metastatic colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma.

What This Means For Patients

雷莫芦单抗 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2014) — Sources
• EMA — Approved (2014) — Sources
• NMPA — Approved (2022) — Sources

Pivotal Clinical Evidence

• RAINBOW — Wilke et al., Lancet Oncol 2014 (NCT01170663) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza
• https://www.nmpa.gov.cn/